EDINBURGH, Scotland, April 25, 2014 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient") (Nasdaq:QTNTU), an established, commercial-stage diagnostics company, today announced the pricing of its initial public offering of 5,000,000 units, each consisting of one ordinary share and one warrant to purchase 0.8 of one ordinary share, at a price of $8.00 per unit. The warrants will be exercisable at an exercise price of $8.80 per whole ordinary share. In addition, Quotient has granted the underwriters a 30-day option to purchase up to an additional 750,000 units at the initial public offering price. All of the units are being offered by Quotient.
The units are expected to begin trading today, April 25, 2014, on the NASDAQ Global Market under the ticker symbol "QTNTU." The ordinary shares and warrants comprising the units will begin trading separately on the NASDAQ Global Market under the symbols "QTNT" and "QTNTW," respectively, on the first trading day following the expiration of the underwriters' 30-day over-allotment option, at which time trading of the units will be suspended and the units will be delisted. The offering is expected to close on April 30, 2014, pending customary closing conditions.
UBS Investment Bank, Baird and Cowen and Company are acting as joint book-running managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (SEC) on April 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. When available, copies of the final prospectus may be obtained from: UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, or by telephone at 1-888-827-7275; or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, Telephone: 800-792-2473 or email firstname.lastname@example.org; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140.
About Quotient Limited
Quotient Limited is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests for blood grouping and serological disease screening. Quotient is developing MosaiQTM, its proprietary technology platform, to offer a breadth of diagnostic tests that is unmatched by any commercially available transfusion diagnostic instrument platform. Quotient's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins (near Geneva), Switzerland.
CONTACT: Stephen Unger email@example.comSource:Quotient Biodiagnostics, Inc.